BRPI1006260B8 - soluções para hemodiálise e diálise peritoneal compreendendo um ou mais compostos de creatina - Google Patents
soluções para hemodiálise e diálise peritoneal compreendendo um ou mais compostos de creatinaInfo
- Publication number
- BRPI1006260B8 BRPI1006260B8 BRPI1006260A BRPI1006260A BRPI1006260B8 BR PI1006260 B8 BRPI1006260 B8 BR PI1006260B8 BR PI1006260 A BRPI1006260 A BR PI1006260A BR PI1006260 A BRPI1006260 A BR PI1006260A BR PI1006260 B8 BRPI1006260 B8 BR PI1006260B8
- Authority
- BR
- Brazil
- Prior art keywords
- creatine
- patients
- dialysis
- solutions
- hemodialysis
- Prior art date
Links
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical class NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 title abstract 10
- 238000000502 dialysis Methods 0.000 title abstract 4
- 238000001631 haemodialysis Methods 0.000 title abstract 2
- 230000000322 hemodialysis Effects 0.000 title abstract 2
- 229960003624 creatine Drugs 0.000 abstract 4
- 239000006046 creatine Substances 0.000 abstract 4
- 239000012141 concentrate Substances 0.000 abstract 3
- 239000000385 dialysis solution Substances 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- -1 creatine compound Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 210000000601 blood cell Anatomy 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000002939 deleterious effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000007407 health benefit Effects 0.000 abstract 1
- 239000000004 hemodialysis solution Substances 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 239000002357 osmotic agent Substances 0.000 abstract 1
- 230000035790 physiological processes and functions Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 230000009469 supplementation Effects 0.000 abstract 1
- 238000011277 treatment modality Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
soluções para hemodiálise e diálise peritoneal compreendendo um ou mais compostos de creatina. a presente invenção se refere a uma solução para hemodiálise ou a um concentrado da mesma, compreendendo composto(s) de creatina, e à aplicação de composto(s) de creatina para preparação de uma solução para diálise ou de um concentrado da mesma. além disso, a presente invenção é dirigida a um método para a preparação de soluções e concentrados para diálise contendo creatina. em adição a presente invenção é dirigida a um método para tratamento de paciente com falência renal dependentes de diálise com compostos de creatina e para fornecer uma variedade de beneficiosos à saúde significativos e aperfeiçoamento dos parâmetros de qualidade de vida para pacientes de diálise. isso é alcançado por suporte e aperfeiçoamento das funções fisiológicas dos órgãos e das células dos pacientes via a entrega de compostos de creatina aos pacientes, e por proteção dos órgãos e das células (especificamente incluindo as células do sangue) destes pacientes contra efeitos deletérios de uma variedade de estressores celulares endógenos e exógenos, que estão ligados ao estado da doenças ou às modalidades tratamento clinico. além disso, em soluções para diálise peritoreal, a creatina pode ser usada como um agente osmótico prevenindo os efeitos colaterais causados por suplementação com elevados teores em glicose.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09005038.6 | 2009-04-06 | ||
| EP09005038 | 2009-04-06 | ||
| PCT/CH2010/000065 WO2010115291A1 (en) | 2009-04-06 | 2010-03-10 | Hemodialysis and peritoneal dialysis solutions comprising one or more creatine compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI1006260A2 BRPI1006260A2 (pt) | 2017-01-17 |
| BRPI1006260B1 BRPI1006260B1 (pt) | 2020-11-17 |
| BRPI1006260B8 true BRPI1006260B8 (pt) | 2021-05-25 |
Family
ID=42111284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1006260A BRPI1006260B8 (pt) | 2009-04-06 | 2010-03-10 | soluções para hemodiálise e diálise peritoneal compreendendo um ou mais compostos de creatina |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9248112B2 (pt) |
| EP (1) | EP2416770B1 (pt) |
| JP (1) | JP6130666B2 (pt) |
| CN (1) | CN102421431B (pt) |
| AU (1) | AU2010234206B2 (pt) |
| BR (1) | BRPI1006260B8 (pt) |
| CA (1) | CA2757327C (pt) |
| EA (1) | EA025137B1 (pt) |
| ES (1) | ES2615204T3 (pt) |
| IL (1) | IL215504A (pt) |
| PL (1) | PL2416770T3 (pt) |
| WO (1) | WO2010115291A1 (pt) |
| ZA (1) | ZA201107715B (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102573828B (zh) * | 2009-07-24 | 2018-02-23 | 克雷勒内有限公司 | 通过施用肌酸化合物的透析患者中的细胞保护 |
| ES2382513B2 (es) * | 2012-05-07 | 2012-09-24 | Luiz Guilherme STARK AROEIRA | Solución de diálisis que contiene al menos un antagonista de CCR2 |
| CN102973599B (zh) * | 2012-12-13 | 2014-04-23 | 天津金耀集团有限公司 | 腹膜透析液（乳酸盐）组合物 |
| WO2014197806A2 (en) * | 2013-06-07 | 2014-12-11 | Allena Pharmaceuticals, Inc. | Compositions, methods, and devices for dialysis |
| WO2017084682A1 (en) | 2015-11-20 | 2017-05-26 | Hepa Wash Gmbh | Method for extracorporeal carbon dioxide removal |
| WO2017084683A1 (en) | 2015-11-20 | 2017-05-26 | Hepa Wash Gmbh | Method for extracorporeal lung support |
| PL3429657T3 (pl) | 2016-03-14 | 2022-08-22 | Advitos Gmbh | Systemy albo aparatury dla przeprowadzania dializy |
| SG11201900588YA (en) * | 2016-08-11 | 2019-02-27 | Cellix Bio Private Ltd | Compositions and methods for the treatment of irritable bowel syndrome |
| EP3600347A1 (en) * | 2017-03-28 | 2020-02-05 | Advitos GmbH | Compositions and methods for regenerating carrier protein-containing multiple pass albumin dialysis fluid |
| IL270771B2 (en) | 2017-05-22 | 2023-12-01 | Advitos Gmbh | Methods and systems for removing carbon dioxide |
| WO2019079765A1 (en) * | 2017-10-20 | 2019-04-25 | University Of Georgia Research Foundation, Inc. | SURFACES AND COATING COMPOSITIONS COMPRISING ANTIFOULING, ANTITHROMBOTIC AND ANTIBACTERIAL PROPERTIES AND METHODS OF PREPARATION THEREOF |
| CN107890568A (zh) * | 2017-10-31 | 2018-04-10 | 华仁药业股份有限公司 | 一种低危害的血液滤过置换液及其制备工艺 |
| KR101864384B1 (ko) * | 2017-12-11 | 2018-06-04 | (주)나노스템 | 콜린 알포세레이트를 유효성분으로 하는 쥐남의 치료, 개선 또는 예방용 조성물 및 방법 |
| GB201801633D0 (en) * | 2018-02-01 | 2018-03-21 | Ogorman Edward | Sports supplements based on liquid creatine |
| CA3113377A1 (en) | 2018-10-11 | 2020-04-16 | Sanifit Therapeutics S.A. | Inositol phosphates for the treatment of ectopic calcification |
| CN114903998A (zh) * | 2021-02-07 | 2022-08-16 | 大连医科大学附属第二医院 | 渗透压保护防治腹膜纤维化和超滤衰竭 |
| WO2026011268A1 (de) * | 2024-07-08 | 2026-01-15 | Crearene Ag | Kreatinverbindung zur prophylaxe und behandlung des kreatinmangels und den damit verbundenen symptomen in hämodialyse-patienten |
| WO2026011269A1 (de) * | 2024-07-08 | 2026-01-15 | Crearene Ag | Dosierungsformulierung für eine dialyselösung zur prophylaxe und behandlung des kreatinmangels und den damit verbundenen symptomen in peritonealdialyse-patienten |
| WO2026011267A1 (de) * | 2024-07-08 | 2026-01-15 | Crearene Ag | Dialyselösung zur verwendung bei der prophylaxe und behandlung des kreatinmangels in patienten |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4604379A (en) * | 1984-06-18 | 1986-08-05 | Curators Of The University Of Missouri | Dialysis solutions containing cross-linked gelatin |
| FR2614219B1 (fr) * | 1987-04-23 | 1993-07-09 | Materiels Annexes Dialyse | Procede de fabrication de granules destines a la preparation de solutions de dialyse et installation pour sa mise en oeuvre. |
| US5827820A (en) * | 1992-04-06 | 1998-10-27 | Baxter International Inc. | Aqueous peritoneal dialysis solution |
| ATE332127T1 (de) | 1994-11-08 | 2006-07-15 | Avicena Group Inc | Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose |
| EP0854712B1 (en) | 1995-10-11 | 2003-05-07 | Avicena Group, Inc. | Use of creatine analogues for the treatment of disorders of glucose metabolism |
| ATE424467T1 (de) * | 1999-05-11 | 2009-03-15 | Cellfree Sciences Co Ltd | Zubereitung, die einen zellextrakt zur herstellung eines zellfreien proteins enthalten und vorrichtung zur herstellung eines zellfreien proteins |
| AU5636300A (en) | 1999-06-25 | 2001-01-31 | Avicena Group, Inc. | Use of creatine or creatine analogs for the prevention and treatment of transmissible spongiform encephalopathies |
| US6242491B1 (en) | 1999-06-25 | 2001-06-05 | Rima Kaddurah-Daouk | Use of creatine or creatine compounds for skin preservation |
| US20030013767A1 (en) * | 2001-07-13 | 2003-01-16 | Samuel Bessman | Method of treating weight loss using creatine |
| EP1567180A4 (en) | 2002-06-04 | 2010-03-10 | Avicena Group Inc | METHOD FOR THE TREATMENT OF COGNITIVE DYSFUNCTION BY MODULATING THE CHANGE OF ENERGY REPLACEMENT IN THE BRAIN |
| AU2007249847A1 (en) | 2006-05-11 | 2007-11-22 | Avicena Group, Inc. | Methods of treating a neurological disorder with creatine monohydrate |
| WO2007133731A2 (en) | 2006-05-11 | 2007-11-22 | Avicena Group, Inc. | Creatine-ligand compounds and methods of use thereof |
| DE102006050931A1 (de) * | 2006-10-28 | 2008-04-30 | Alzchem Trostberg Gmbh | Feste oder wässrige alkalische Zubereitung auf Basis einer Kreatin-Komponente, Verfahren zu deren Herstellung und ihre Verwendung |
| US20080206170A1 (en) | 2006-12-07 | 2008-08-28 | Belinda Tsao Nivaggioli | Creatine compositions for skin treatment |
| WO2008124151A2 (en) | 2007-04-09 | 2008-10-16 | Avicena Group, Inc. | Use of creatine compounds for the treatment of eye disorders |
| WO2008137137A1 (en) | 2007-05-03 | 2008-11-13 | Avicena Group, Inc. | Creatine ascorbyl derivatives and methods of use thereof |
| US20090105196A1 (en) | 2007-06-22 | 2009-04-23 | Belinda Tsao Nivaggioli | Use of creatine compounds to treat dermatitis |
-
2010
- 2010-03-10 ES ES10707804.0T patent/ES2615204T3/es active Active
- 2010-03-10 EA EA201101463A patent/EA025137B1/ru not_active IP Right Cessation
- 2010-03-10 WO PCT/CH2010/000065 patent/WO2010115291A1/en not_active Ceased
- 2010-03-10 AU AU2010234206A patent/AU2010234206B2/en active Active
- 2010-03-10 US US13/263,189 patent/US9248112B2/en active Active
- 2010-03-10 EP EP10707804.0A patent/EP2416770B1/en active Active
- 2010-03-10 JP JP2012503842A patent/JP6130666B2/ja active Active
- 2010-03-10 CN CN201080018482.3A patent/CN102421431B/zh active Active
- 2010-03-10 PL PL10707804T patent/PL2416770T3/pl unknown
- 2010-03-10 BR BRPI1006260A patent/BRPI1006260B8/pt active IP Right Grant
- 2010-03-10 CA CA2757327A patent/CA2757327C/en active Active
-
2011
- 2011-10-03 IL IL215504A patent/IL215504A/en active IP Right Grant
- 2011-10-21 ZA ZA2011/07715A patent/ZA201107715B/en unknown
-
2016
- 2016-01-11 US US14/993,079 patent/US20160120829A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010234206A1 (en) | 2011-11-03 |
| IL215504A (en) | 2017-04-30 |
| JP6130666B2 (ja) | 2017-05-17 |
| BRPI1006260A2 (pt) | 2017-01-17 |
| CN102421431A (zh) | 2012-04-18 |
| HK1164157A1 (en) | 2012-09-21 |
| JP2012522812A (ja) | 2012-09-27 |
| PL2416770T3 (pl) | 2017-06-30 |
| AU2010234206A2 (en) | 2011-11-10 |
| ES2615204T3 (es) | 2017-06-05 |
| AU2010234206B2 (en) | 2016-10-27 |
| EA025137B1 (ru) | 2016-11-30 |
| US20160120829A1 (en) | 2016-05-05 |
| CA2757327C (en) | 2017-12-12 |
| EP2416770B1 (en) | 2016-10-26 |
| IL215504A0 (en) | 2011-12-29 |
| EP2416770A1 (en) | 2012-02-15 |
| CA2757327A1 (en) | 2010-10-14 |
| WO2010115291A1 (en) | 2010-10-14 |
| EA201101463A1 (ru) | 2012-03-30 |
| US9248112B2 (en) | 2016-02-02 |
| ZA201107715B (en) | 2012-07-25 |
| CN102421431B (zh) | 2019-04-02 |
| US20120101069A1 (en) | 2012-04-26 |
| BRPI1006260B1 (pt) | 2020-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1006260B8 (pt) | soluções para hemodiálise e diálise peritoneal compreendendo um ou mais compostos de creatina | |
| Ma et al. | Combining ECMO with IABP for the treatment of critically Ill adult heart failure patients | |
| Poulianiti et al. | Systemic redox imbalance in chronic kidney disease: a systematic review | |
| Davenport et al. | Higher convection volume exchange with online hemodiafiltration is associated with survival advantage for dialysis patients: the effect of adjustment for body size | |
| BR112013032265A2 (pt) | métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano | |
| Guarracino et al. | β-Blockers to optimize peripheral oxygenation during extracorporeal membrane oxygenation: a case series | |
| EA200970944A1 (ru) | Применение биполярных транскаротиноидов в качестве предварительного лечения при лечении заболевания периферических сосудов | |
| de Sequera et al. | Prospective randomized multicenter study to demonstrate the benefits of haemodialysis without acetate (with citrate): ABC-treat Study. Acute effect of citrate | |
| Nakao et al. | Modified del Nido cardioplegia and its evaluation in a piglet model | |
| Kampmeier et al. | Effects of resuscitation with human albumin 5%, hydroxyethyl starch 130/0.4 6%, or crystalloid on kidney damage in an ovine model of septic shock | |
| Morgan et al. | Acid-base effects of a bicarbonate-balanced priming fluid during cardiopulmonary bypass: comparison with Plasma-Lyte 148. A randomised single-blinded study | |
| BR112015009291A2 (pt) | métodos para o controle da pressão arterial e redução da dispnéia na insuficiência cardíaca | |
| CN1390118A (zh) | 用于静脉输注的葡萄糖和胰岛素液体组合物 | |
| Grände | Time out for albumin or a valuable therapeutic component in severe head injury? | |
| Akıncı et al. | Successful resuscitation of a patient with continuous venovenous hemodiafiltration following intoxication from verapamil and trandolapril | |
| Gibson et al. | Fluid management | |
| HRP20192306T1 (hr) | Upotreba spojeva vanadija u održavanju normoglikemije kod sisavaca | |
| Pieri et al. | Impact of cytosorb treatment on drugs’ need in critically ill patients | |
| Baizhigitov et al. | Methods of modified ultrafiltration in the surgical correction of transposition of the great arteries in newborns | |
| Márquez et al. | Kidney Transplant in Pediatric Patient With Heart Failure: Case Report | |
| Hirata et al. | Hyperkalemia by Euro-Collins solution in anesthesia for renal transplantation: a case report | |
| Anıl et al. | The first succesful extracorporeal membranous oxygenation treatment in a child with refractory fulminant myocarditis in Turkey | |
| Punia et al. | Acquired perforating dermatosis in a patient of diabetes mellitus with chronic kidney disease | |
| Alipour et al. | Metformin-Induced Lactic Acidosis in a Patient with End-Stage Renal Disease | |
| Burki et al. | A novel extracorporeal CO2 removal system: application of the hemolung in patients with hypercapnic respiratory failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B25A | Requested transfer of rights approved |
Owner name: CREARENE AG (CH) |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |